• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Feigal Ellen

    6/22/26 4:15:01 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Feigal Ellen

    (Last)(First)(Middle)
    C/O NEXTCURE, INC.
    9000 VIRGINIA MANOR ROAD, SUITE 200

    (Street)
    BELTSVILLE MARYLAND 20705

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    NextCure, Inc. [ NXTC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/18/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$2.0206/18/2026A2,340 (1)06/17/2036Common Stock2,340$02,340D
    Explanation of Responses:
    1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
    /s/ Steven P. Cobourn, as attorney-in-fact for Ellen Feigal06/22/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $NXTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/7/2025$18.00Neutral → Buy
    Ladenburg Thalmann
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

    Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001 Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis Company to be led by a seasoned team of biotech executives: Andrew Cheng, MD, PhD as CEO, President, & C

    7/14/26 6:00:00 AM ET
    $NXTC
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

    BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The virtual KOL Event is accessible here. The event featured: Beryl Manning-Geist

    6/4/26 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

    55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC NextCure to host virtual Key Opinion Leader (KOL) Event June 2, 2026 at 8 AM ET BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere Zaiming) an oncology-focused biopharmaceutical company and a subsid

    6/1/26 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Borgman Anne Elizabeth

    4 - NextCure, Inc. (0001661059) (Issuer)

    6/22/26 4:14:58 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Jones Elaine V

    4 - NextCure, Inc. (0001661059) (Issuer)

    6/22/26 4:15:01 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Feigal Ellen

    4 - NextCure, Inc. (0001661059) (Issuer)

    6/22/26 4:15:01 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NextCure upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded NextCure from Neutral to Buy and set a new price target of $18.00

    11/7/25 8:06:56 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded NextCure from Buy to Neutral

    11/4/22 1:03:13 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on NextCure with a new price target

    Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

    3/1/22 7:18:07 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    SEC Filings

    View All

    SEC Form 425 filed by NextCure Inc.

    425 - NextCure, Inc. (0001661059) (Subject)

    7/16/26 5:28:48 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by NextCure Inc.

    425 - NextCure, Inc. (0001661059) (Subject)

    7/14/26 7:02:44 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NextCure, Inc. (0001661059) (Filer)

    7/14/26 7:00:58 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    View All

    NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

    BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

    4/4/24 7:05:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

    BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

    10/27/22 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

    3/4/21 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Financials

    Live finance-specific insights

    View All

    NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

    BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

    11/1/21 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/14/24 6:59:21 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/13/24 4:06:36 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NextCure Inc.

    SC 13G - NextCure, Inc. (0001661059) (Subject)

    6/27/24 4:47:26 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care